Federal Register
Notice: FDA’s Psychopharmacologic Drugs Advisory Committee will be meet 9/7-8, from 8 a.m. to 5 p.m. at the Hilton Hotel, The Ballrooms, 620 Perry Pkwy., Gaithersburg, MD 20877. On 9/7, the committee will discuss Janssen/Johnson & Johnson Pharmaceutical Research and Development’s NDA 21-999, paliperidone extended-release tablets, for treating schizophrenia. On 9/8 the committee will discuss Wyeth Pharmaceutical’s NDA 21- 992, desvenlafaxine succinate ER tablets for treating major depressive disorder. Contact Cicely Reese, (301) 827-7001.The background material will be posted no later than the day before the meeting on FDA's Web site at
http://frwebgate.access.gpo.gov/cgi-bin/leaving.cgi?from=leavingFR.html&log=linklog&to=http://www.fda.gov/ohrms/dockets/ac/acmenu.htm under the heading "Psychopharmacologic Drugs Advisory Committee (PDAC)." (Click on the year 2006 and scroll down to PDAC meetings.). To view this notice, click here.